PCG Committees

PCG Disease Site Committees

John-Chang
Disease Site Committee Chair

John Chang, MD

Northwestern Medicine Chicago Proton Center

Disease Site Sub-Chairs

Oren-Cahlon
Breast

Oren Cahlon, MD

Princeton ProCure New Jersey Proton Center

Dr. Cahlon is a nationally recognized leader in the use of proton therapy for breast cancer.  He serves as the Medical Director of the Princeton Procure Proton Center in Somerset, NJ, and also serves as the Director of Proton Therapy at Memorial Sloan Kettering Cancer Center (MSKCC).  In these roles, Dr. Cahlon oversees medical operations, clinical research and treatment protocols for the Procure Proton Therapy Center.  As Medical Director of the NJ facility, Dr. Cahlon has played an integral role in development of a clinical and research partnership with the New York Proton Center Consortium.  This collaboration has led to increased access to proton therapy for patients in the New York Metro Area.

In conjunction with collaborators at ProCure and MSKCC, Dr. Cahlon has published research papers on the potential benefits of proton therapy for breast cancer.  He is frequently invited to speak nationally and internationally on the use of proton therapy for breast cancer and other disease sites.  In addition to his role as the head of the PCG Breast Cancer Committee, Dr. Cahlon serves as the co-principal investigator of the RADCOMP national trial investigating whether proton therapy improves outcomes for breast cancer patients receiving comprehensive nodal irradiation.

Minesh-Mehta
Central Nervous System

Dr. Minesh Mehta

Miami Cancer Institute 

Dr. Minesh Mehta serves as the Deputy Director and Chief of Radiation Oncology for the Miami Cancer Institute in Miami, Florida. He received his medical degree from the University of Zambia in Lusaka, and, after completing an internship at Ndola Central Hospital in Ndola, Zambia, he completed residency training in radiation oncology at the University of Wisconsin, after which he was appointed to the faculty of the University of Wisconsin School of Medicine in the Department of Human Oncology. He was appointed to Chairman of the Department of Human Oncology in 1997, a position he held for 10 years. Prior to coming to Maryland, from 2010 to 2012, Dr. Mehta was Professor of Radiation Oncology at Northwestern University in Chicago where he was also co-leader of the Robert H. Lurie Cancer Center Solid Tumor Investigational Program. Dr. Mehta has published widely, including several hundred journal articles and book chapters in the fields of thoracic and central nervous system tumors. His research has also involved the areas of radiosensitizers, radioprotectors, and radiation oncology technology, specifically intensity-modulated, image-guided radiation therapy. Dr. Mehta has had responsibilities in several leadership roles, including departmental chairmanship, residency program directorship, medical school course directorship, as well as leadership positions in several national organizations including the American Society of Clinical Oncology, the American Society for Radiation Oncology, and the FDA.

R-Charles-Nichols
Gastrointestinal

R. Charles Nichols, MD

University of Florida Proton Therapy Institute

Dr. Nichols is an Associate Professor in the Department of Radiation Oncology at the UF Health Proton Therapy Institute. He received his undergraduate degree in Economics and Mathematics from Georgetown University in 1983 and his medical degree from Georgetown in 1988. Prior to joining UF Health Proton Therapy Institute, he served as medical director of the Bay Medical Regional Cancer Center in Panama City, Florida. A University of Florida Department of Radiation Oncology faculty member since 2008, he serves as the Radiation Therapy Oncology Group (RTOG) Principal Investigator for both the Jacksonville and Gainesville campuses and serves as the Gastrointestinal Disease Site Committee Chair for PCG.

carlos-vargas-12780472
Genitourinary

Carlos Vargas, MD

Mayo Clinic-Arizona

Dr. Vargas is an Associate Professor in the department of radiation at Mayo Clinic in Arizona. He has been involved in the development and use of proton therapy since 2005. His main interests include development of proton therapy, genitourinary malignancies, and breast cancer.

Rutenberg2
Reirradiation

Michael Rutenberg, PhD, MD

University of Florida Proton Therapy Institute

Dr. Rutenberg is an Assistant Professor at the UF Health Proton Therapy Institute and chairs the PCG Reirradiation Subcommittee. He has conducted research on reirradiation for prostate and lung cancers.  He leads the reirradiation program at the UF Health Proton Therapy Institute, utilizing proton therapy for patients previously treated with radiotherapy. He is a member of the ASTRO Radiation and Cancer Biology Committee of the Science Council.

An alumnus of the University of Florida’s MD/PhD program, Dr. Rutenberg completed medical school at UF and conducted his PhD research at Harvard Medical School. He completed his training at the University of Maryland Medical Center before joining the faculty at the University of Florida.

John-Chang
Head & Neck

John Chang, MD

Northwestern Medicine Chicago Proton Center

Dr. Chang is the Director of Clinical Research for Northwestern Medicine Chicago Proton Center and also serves as the Head & Neck Disease Site committee chair for PCG. He is Board Certified in Radiation Oncology and primarily practices at the Northwestern Medicine Chicago Proton Center. After completing his medical school at the University of Michigan and residency at the University of Pennsylvania, he joined Radiation Oncology Consultants (ROC), where he has been in private practice since 2000. Dr. Chang is the principal investigator for the Radiation Therapy Oncology Group (RTOG) and the Children’s Oncology Group (COG) research program, and is an assistant professor at the Chicago Medical School/Rosalind Franklin School of Medicine and Science. He is a peer review editor for the International Journal of Radiation Oncology, Physics and Biology and the International Journal of Particle Therapy.

Dr. Chang has expertise in the use of conformal 3-D radiation therapy, intensity modulated radiation therapy (IMRT), stereotactic radiosurgery, high dose rate brachytherapy, and permanent brachytherapy (seed implants) and Proton therapy. His areas of interest include head and neck, genitourinary, brain, lung, and pediatric malignancies. He has presented numerous papers, and given lectures on various cancer treatments. He spends his leisure time playing hockey.

When asked why he chose Radiation Oncology, he states, “Although I thoroughly enjoyed research and the technological aspect of medicine early in my career, I longed for patient contact. Radiation Oncology gives me the perfect setting to use my expertise in technology to help my patients fight their disease with the most advanced therapies possible.”

Charles-Simone
Lung

Charles Simone, MD

University of Maryland 

Dr. Charles B. Simone, II is the Medical Director of the Maryland Proton Treatment Center and an Associate Professor of Radiation Oncology at the University of Maryland School of Medicine. He completed his undergraduate and medical school training at the University of Pennsylvania. He completed an internship in internal medicine, and then he completed residency training in radiation oncology at the National Cancer Institute (NCI), National Institutes of Health, where he served as chief resident. Prior to his appointment at University of Maryland, Dr. Simone was an Associate Professor of Radiation Oncology, Chief of Thoracic Oncology at the Hospital of the University of Pennsylvania, and Director of the Penn Mesothelioma and Pleural Program for the University of Pennsylvania Health System.

Dr. Simone treats patients with malignant pleural mesothelioma, lung cancer, and other thoracic malignancies with proton and photon radiation therapy and photodynamic therapy (PDT). He is a National Institutes of Health, National Science Foundation, and Department of Defense funded investigator who performs clinical and translational research investigating the use of proton therapy for thoracic malignancies. He is the Chair of the Proton Collaborative Group (PCG) Lung Committee and the Chair of the American Society for Photobiology (ASP) Education Committee. He is appointed to the NRG Oncology (formerly Radiation Therapy Oncology Group [RTOG]) Lung Cancer Core Committee; NRG Radiation Oncology Committee; NCI Thoracic Malignancies Steering Committee Mesothelioma Working Group; International Thymic Malignancy Interest Group (ITMIG) Research and Infrastructure Committee; ITMIG Thymic Carcinoma Workgroup; American Society for Radiation Oncology (ASTRO) Lung Cancer “Blue Ribbon” Panel; PCG Reirradiation Committee; Particle Therapy Co-Operative Group (PTCOG) Scientific Committee; and multiple PTCOG Clinical Subcommittees.

Brad-Hoppe
Lymphoma

Brad Hoppe, MD, MPH

University of Florida Proton Therapy Institute

Dr. Hoppe is an Associate Professor in the Department of Radiation Oncology at the University of Florida, specializing in the management of patients with Hodgkin lymphoma, non-Hodgkin lymphoma, lung cancer and prostate cancer. He currently holds the James E. Lockwood, Jr., Endowed Chair of Proton Therapy. An established cancer researcher, Dr. Hoppe is the principal investigator on five clinical trials and the author of over 70 published manuscripts and book chapters in various peer-reviewed medical journals, including Journal of Clinical Oncology, Cancer, Journal of Thoracic Oncology, Bone Marrow Transplant, Radiotherapy and Oncology and the International Journal of Radiation Oncology Biology Physics. His research focus has been on reducing side effects of radiation and better understanding patient reported quality of life outcomes among patients with lung cancer, prostate cancer and lymphoma.

Ronny-Rotondo
Pediatrics

Ronny Rotondo, MD

University of Florida Proton Therapy Institute

Dr. Rotondo is a radiation oncologist and University of Florida Clinical Assistant Professor with specialized training in pediatric proton therapy. Dr. Rotondo specializes in pediatric malignancies as well as base of skull and adult central nervous system tumors. He is board certified in radiation oncology clinical practice in Canada and is board eligible in the United States. Prior to joining the UF Health Proton Therapy Institute, he completed his residency training at McGill University in Montreal, Canada. He also completed a one year fellowship in proton radiation therapy at the Massachusetts General Hospital – Harvard University and two years of dedicated fellowship training in pediatric proton radiation therapy at the UF Health Proton Therapy Institute. His work has been published in medical journals and has been presented at national and international conferences. He is a member of the American Medical Association (AMA), American Society for Radiation Oncology (ASTRO), American Society of Clinical Oncology (ASCO), and the Canadian Association of Radiation Oncology (CARO) among others.

Sarcoma

Jonathan Ashman, MD

Mayo Clinic, Arizona

COMING SOON

PCG Publications Committee

84652c3ac7e441778eb22977d3edba48
Publications Committee Chair

Soren M. Bentzen PhD, DMSc

University of Maryland

Søren M. Bentzen, MSc, PhD, DMSc, Professor, Director of the Biostatistics Shared Service, University of Maryland Greenebaum Cancer Center, and Director of the Division of Biostatistics and Bioinformatics, Department of Epidemiology and Public Health, University of Maryland School of Medicine since 2013. Dr. Bentzen is also an Adjunct Professor of Radiobiology and Medical Physics, University of Copenhagen, Denmark. His previous appointments include MD Anderson Cancer Center (1987-1988), Danish Cancer Society/Aarhus University (1988-1997), Gray Laboratory/Mount Vernon Hospital, London (1998-2004), and University of Wisconsin School of Medicine and Public Health (2005-2013) where he was a professor of Human Oncology and held affiliate faculty positions in the departments of Biostatistics & Medical Informatics and in Medical Physics.

Dr. Bentzen received a MSc in physics and mathematics (1981), a PhD in medical image analysis (1986), and a DMSc (doctor of medical science) in quantitative clinical radiobiology (1994), all from Aarhus University, Denmark. He has published >370 original papers and book chapters, and has presented >300 invited lectures. He currently serves on 10 international cancer journal editorial boards. His main research interests include bioeffect modeling; biomathematics; applied biostatistics; clinical trial design; evidence-based medicine; late effects of radiotherapy; clinical radiobiology; integration of data from genomics, proteomics, and molecular imaging into novel therapeutic strategies.

Oren-Cahlon

Oren Cahlon, MD

Princeton ProCure New Jersey Proton Center

Dr. Cahlon is a nationally recognized leader in the use of proton therapy for breast cancer. He serves as the Medical Director of the Princeton Procure Proton Center in Somerset, NJ, and also serves as the Director of Proton Therapy at Memorial Sloan Kettering Cancer Center (MSKCC). In these roles, Dr. Cahlon oversees medical operations, clinical research and treatment protocols for the Procure Proton Therapy Center. As Medical Director of the NJ facility, Dr. Cahlon has played an integral role in development of a clinical and research partnership with the New York Proton Center Consortium. This collaboration has led to increased access to proton therapy for patients in the New York Metro Area.

In conjunction with collaborators at ProCure and MSKCC, Dr. Cahlon has published research papers on the potential benefits of proton therapy for breast cancer. He is frequently invited to speak nationally and internationally on the use of proton therapy for breast cancer and other disease sites. In addition to his role as the head of the PCG Breast Cancer Committee, Dr. Cahlon serves as the co-principal investigator of the RADCOMP national trial investigating whether proton therapy improves outcomes for breast cancer patients receiving comprehensive nodal irradiation.

John-Chang

John Chang, MD

Northwestern Medicine Chicago Proton Center

Dr. Chang is the Director of Clinical Research for Northwestern Medicine Chicago Proton Center and also serves as the Head & Neck Disease Site committee chair for PCG. He is Board Certified in Radiation Oncology and primarily practices at the Northwestern Medicine Chicago Proton Center. After completing his medical school at the University of Michigan and residency at the University of Pennsylvania, he joined Radiation Oncology Consultants (ROC), where he has been in private practice since 2000. Dr. Chang is the principal investigator for the Radiation Therapy Oncology Group (RTOG) and the Children’s Oncology Group (COG) research program, and is an assistant professor at the Chicago Medical School/Rosalind Franklin School of Medicine and Science. He is a peer review editor for the International Journal of Radiation Oncology, Physics and Biology and the International Journal of Particle Therapy.

Halasz

Lia M. Halasz, MD

University of Washington, SCCA Proton Center

Dr. Halasz is a radiation oncologist with expertise in brain and spinal tumors, proton beam radiation therapy, and genitourinary tumors, particularly prostate cancer. She treats patients at UW Medical Center, Harborview Medical Center, and SCCA Proton Therapy.

Brad-Hoppe

Brad Hoppe, MD, MPH

University of Florida Proton Therapy Institute

Dr. Hoppe is an Associate Professor in the Department of Radiation Oncology at the University of Florida, specializing in the management of patients with Hodgkin lymphoma, non-Hodgkin lymphoma, lung cancer and prostate cancer. He currently holds the James E. Lockwood, Jr., Endowed Chair of Proton Therapy. An established cancer researcher, Dr. Hoppe is the principal investigator on five clinical trials and the author of over 70 published manuscripts and book chapters in various peer-reviewed medical journals, including Journal of Clinical Oncology, Cancer, Journal of Thoracic Oncology, Bone Marrow Transplant, Radiotherapy and Oncology and the International Journal of Radiation Oncology Biology Physics. His research focus has been on reducing side effects of radiation and better understanding patient reported quality of life outcomes among patients with lung cancer, prostate cancer and lymphoma.

Blog-Carl-Rossi

Carl Rossi, Jr, MD

Scripps Proton Therapy Center

Dr. Rossi is a board certified radiation oncologist, specializing in proton beam therapy, specifically for prostate cancers and lymphomas and serves as the medical director of Scripps Proton Therapy Center. Dr. Rossi previously served as chief of genitourinary and lymphoma radiation oncology services at Loma Linda University Medical Center and also served as an associate professor of radiation oncology. During his tenure at Loma Linda, Dr. Rossi treated more than 9,000 prostate cancer patients with proton therapy. Dr. Rossi has published more than 20 peer-reviewed articles, as well as contributed chapters to definitive textbooks on radiation oncology. Dr. Rossi earned his medical degree from Loyola University Stritch School of Medicine in 1988 and did his internship and residency at Loma Linda University Medical Center in radiation oncology. Dr. Rossi currently serves as the PCG Principal Investigator for Scripps Proton Therapy Center and is a member of both the PCG GenitoUrinary and Lymphoma Disease Site Committees.

Les Yonemoto Headshot

Leslie T. Yonemoto, MD

Dr. Les Yonemoto is a radiation oncologist who has treated over 2,500 patients with proton therapy since 1992.   He has assisted multiple proton centers with clinical, operational and business development since 1996.

He earned the following degrees:
Bachelor of Science in Electrical Engineering and Computer Sciences at University of California – Berkeley,  Master of Business Administration at Arizona State University,  Doctor of Medicine at Johns Hopkins University School of Medicine,  Radiation Oncology Residency at Loma Linda University Medical Center and MD Anderson Cancer Center

Dr. Yonemoto has authored and coauthored many peer-reviewed articles and has lectured on cancer research, cancer treatment, and proton therapy in many domestic and international forums and has been featured in several national and regional news programs.

 

PCG Data Safety Monitoring Board

Robert-Miller
Data Safety Monitoring Board Chair

Robert Miller, MD

Mayo Clinic

Dr. Miller is a Professor of Radiation Oncology at Mayo Clinic in Jacksonville, Florida. He also serves as Medical Director for Mayo Clinic Operations in Northfield, Minnesota and is Vice Chair Board of Trustees Mayo Clinic Health System Albert Lea-Austin, Minnesota. He is a member of the Mayo Clinic Cancer Practice Executive Committee. As primary investigator, he has led six multi-institutional randomized clinical trials focused on symptom control in radiotherapy. He received an MS in Radiological Medical Physics in 1990 and an MD in 1993 from the University of Kentucky, as well as an MBA from the University of Oxford in the United Kingdom in 2013. He is Editor in Chief of ASTRO’s Advances in Radiation Oncology and Pagepress Publications’ (Pavia, Italy) Rare Tumors.

DSMB Committee Members

Richard Amos, PhD, Medical Physicist , MD Anderson

Jeffery Buchsbaum, MD, Indiana University Health

Mark Pankuch, PhD, Director of Medical Physics, Northwestern Medicine Chicago Proton Center

Eugen Hug, MD, ProCure New Jersey

Brad Hoppe, MD, MPH, University of Florida Proton Therapy Institute

Carlos Vargas, MD, Mayo Clinic

Paige Dorn, MD, Northwestern Medicine Chicago Proton Center

HsiWen Chien, PhD, Medical Physicist, Procure Oklahoma City

Stella Flampouri, PhD, Medical Physicist, University of Florida Proton Therapy Institute

Zuofeng Li, DSc, Director of Medical Physics, University of Florida Proton Therapy Institute

Andrew Chang, MD, ProCure Oklahoma City, Scripps Health, Hampton University Proton Therapy Institute